Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging

Kanako Inaba; Katsutoshi Oda; Kazuhiro Aoki; Kenbun Sone; Yuji Ikeda; Aki Miyasaka; Tomoko Kashiyama; Tomohiko Fukuda; Chinami Makii; Takahide Arimoto; Osamu Wada-Hiraike; Kei Kawana; Tetsu Yano; Yutaka Osuga; Tomoyuki Fujii

doi:10.18632/oncotarget.8807

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging

Kanako Inaba _, Katsutoshi Oda, Kazuhiro Aoki, Kenbun Sone, Yuji Ikeda, Aki Miyasaka, Tomoko Kashiyama, Tomohiko Fukuda, Chinami Makii, Takahide Arimoto, Osamu Wada-Hiraike, Kei Kawana, Tetsu Yano, Yutaka Osuga and Tomoyuki Fujii

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:29577-29591. https://doi.org/10.18632/oncotarget.8807

Metrics: PDF 1390 views | HTML 2772 views | ?

Abstract

Kanako Inaba1, Katsutoshi Oda1, Kazuhiro Aoki2, Kenbun Sone1, Yuji Ikeda1, Aki Miyasaka1, Tomoko Kashiyama1, Tomohiko Fukuda1, Chinami Makii1, Takahide Arimoto1, Osamu Wada-Hiraike1, Kei Kawana1, Tetsu Yano3, Yutaka Osuga1, Tomoyuki Fujii1

1Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan

2Imaging Platform for Spatio-Temporal Information, Graduate School of Medicine, Kyoto University, Kyoto, Japan

3Department of Obstetrics and Gynecology, National Center for Global Health and Medicine, Tokyo, Japan

Correspondence to:

Katsutoshi Oda, email: [email protected]

Keywords: ovarian mucinous carcinoma, MAPK pathway, PI3K/mTOR pathway, molecular target therapy, FRET imaging

Received: November 15, 2015 Accepted: March 29, 2016 Published: April 18, 2016

ABSTRACT

The aim of this study was to clarify the synergistic effects of dual inhibition of the PI3K/mTOR and MAPK pathways in ovarian mucinous carcinoma (OMC) cells, using fluorescence resonance energy transfer (FRET) imaging. We exposed 6 OMC cell lines to a PI3K/mTOR inhibitor (voxtalisib, SAR245409) and/or a MEK inhibitor (pimasertib), and evaluated synergistic effects using the Chou–Talalay method. Then, S6K (PI3K pathway) and ERK (MAPK pathway) kinase activities, and their individual proliferative or cytotoxic effects were calculated by time-lapse FRET imaging. In combination with SAR245409, pimasertib (30 nM) synergistically inhibited cell growth (combination indexes: 0.03–0.5) and induced apoptosis in all 6 OMC cell lines. FRET-imaging results demonstrated that ERK inhibition induced both anti-proliferation and apoptosis in a dose-dependent manner in both MCAS and OAW42 cells. However, S6K inhibition suppressed proliferation in a threshold manner in both cell lines, although apoptosis was only induced in OAW42 cells. These results demonstrated that combined PI3K/mTOR and MEK inhibition exhibited synergistic antitumor effects in OMC cells and that FRET imaging is useful for analyzing kinase activities in live cells and elucidating their cytostatic and cytotoxic effects.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8807

Publication Alerts

Research Papers:

Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging

Abstract